CLEVELAND, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2023 before the market opens on Tuesday, February 27, 2024. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating highlights and financial results.
To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from other locations. A live webcast of the conference call can be accessed at this link or via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health, along with the accompanying materials. A replay of the webcast will be available later in the day on February 27th.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Contacts
Jason Peterson
Vice President & Treasurer, Sotera Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
Kristin Gibbs
Chief Marketing Officer, Sotera Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$12.88 |
Daily Change: | -0.37 -2.79 |
Daily Volume: | 311,202 |
Market Cap: | US$3.650B |
November 05, 2024 September 04, 2024 August 05, 2024 May 30, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB